---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038617"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:25:17.046346+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine Q2: positive CGD clinical data, $144M offering, cash runway into 2027

## Summary
- First clinical proof-of-concept for Prime Editing: two patients in CGD trial showed restored NADPH oxidase activity above clinical benefit threshold.
- Completed $144.2M follow-on offering in August 2025; cash balance pro-forma $259.6M as of June 30, 2025.
- Secured up to $24M from Cystic Fibrosis Foundation to advance CF program targeting G542X mutation.
- Allan Reine named CEO in May 2025; strategic restructuring and workforce reduction expected to cut cash needs by half through 2027.
- Net loss of $52.6M in Q2 2025 (vs. $55.3M in Q2 2024); R&D expenses down to $41.4M.

## SEC filing metadata
- accession: 0001628280-25-038617
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828025038617/0001628280-25-038617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828025038617/prme-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038617
- JSON: https://secwatch.observer/filing/0001628280-25-038617.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.